Elevation Oncology (ELEV) Competitors $0.58 +0.00 (+0.21%) (As of 10:31 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ELEV vs. RAIN, SCYX, BOLT, SBBP, IPHA, SGMT, IXHL, BDTX, TELO, and SKYEShould you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Rain Oncology (RAIN), SCYNEXIS (SCYX), Bolt Biotherapeutics (BOLT), Strongbridge Biopharma (SBBP), Innate Pharma (IPHA), Sagimet Biosciences (SGMT), Incannex Healthcare (IXHL), Black Diamond Therapeutics (BDTX), Telomir Pharmaceuticals (TELO), and Skye Bioscience (SKYE). These companies are all part of the "medical" sector. Elevation Oncology vs. Rain Oncology SCYNEXIS Bolt Biotherapeutics Strongbridge Biopharma Innate Pharma Sagimet Biosciences Incannex Healthcare Black Diamond Therapeutics Telomir Pharmaceuticals Skye Bioscience Elevation Oncology (NASDAQ:ELEV) and Rain Oncology (NASDAQ:RAIN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, community ranking, dividends, earnings, profitability, valuation and institutional ownership. Does the MarketBeat Community believe in ELEV or RAIN? Elevation Oncology received 4 more outperform votes than Rain Oncology when rated by MarketBeat users. Likewise, 73.17% of users gave Elevation Oncology an outperform vote while only 52.00% of users gave Rain Oncology an outperform vote. CompanyUnderperformOutperformElevation OncologyOutperform Votes3073.17% Underperform Votes1126.83% Rain OncologyOutperform Votes2652.00% Underperform Votes2448.00% Does the media prefer ELEV or RAIN? In the previous week, Elevation Oncology's average media sentiment score of -0.25 beat Rain Oncology's score of -0.29 indicating that Elevation Oncology is being referred to more favorably in the media. Company Overall Sentiment Elevation Oncology Neutral Rain Oncology Neutral Which has more volatility & risk, ELEV or RAIN? Elevation Oncology has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, Rain Oncology has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Do analysts rate ELEV or RAIN? Elevation Oncology presently has a consensus price target of $7.80, indicating a potential upside of 1,239.52%. Given Elevation Oncology's stronger consensus rating and higher possible upside, equities research analysts plainly believe Elevation Oncology is more favorable than Rain Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elevation Oncology 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Rain Oncology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ELEV or RAIN more profitable? Elevation Oncology's return on equity of -59.73% beat Rain Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Elevation OncologyN/A -59.73% -40.05% Rain Oncology N/A -82.96%-68.31% Do insiders and institutionals hold more shares of ELEV or RAIN? 83.7% of Elevation Oncology shares are held by institutional investors. Comparatively, 65.8% of Rain Oncology shares are held by institutional investors. 8.1% of Elevation Oncology shares are held by company insiders. Comparatively, 17.4% of Rain Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation & earnings, ELEV or RAIN? Elevation Oncology is trading at a lower price-to-earnings ratio than Rain Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElevation OncologyN/AN/A-$45.70M-$0.82-0.71Rain OncologyN/AN/A-$75.72M-$2.06-0.59 SummaryElevation Oncology beats Rain Oncology on 12 of the 14 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Elevation Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELEV vs. The Competition Export to ExcelMetricElevation OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.43M$2.95B$5.07B$8.80BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-0.7116.8789.5613.60Price / SalesN/A280.301,224.8087.40Price / CashN/A169.3839.4536.27Price / Book0.504.436.976.33Net Income-$45.70M-$41.63M$119.04M$225.93M7 Day Performance0.34%-5.15%-1.78%-0.96%1 Month Performance-0.50%-6.91%-3.59%1.06%1 Year Performance23.68%25.64%31.64%26.59% Elevation Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELEVElevation Oncology2.017 of 5 stars$0.58+0.2%$7.80+1,239.5%+24.0%$34.43MN/A-0.7140Gap UpRAINRain OncologyN/A$1.21flatN/AN/A$44.02MN/A-0.5963SCYXSCYNEXIS2.2075 of 5 stars$1.20+1.7%N/A-28.5%$45.54M$140.14M0.0060Positive NewsBOLTBolt Biotherapeutics3.3839 of 5 stars$0.56-2.5%$3.50+529.5%-37.7%$21.28M$7.88M0.00100SBBPStrongbridge BiopharmaN/A$2.00flatN/A+0.0%$135.66M$30.73M-2.5672Analyst ForecastGap DownIPHAInnate Pharma2.2495 of 5 stars$1.69+13.5%$11.50+582.3%-32.8%$136.48M$66.71M0.00220News CoverageGap UpSGMTSagimet Biosciences2.1861 of 5 stars$4.41-2.4%$21.60+389.8%+50.2%$135.26M$2M0.008IXHLIncannex Healthcare1.3552 of 5 stars$2.09flatN/A+132.2%$132.67M$10,000.000.003BDTXBlack Diamond Therapeutics2.8436 of 5 stars$2.33-4.1%$15.50+565.2%+8.0%$131.83MN/A0.0090Positive NewsTELOTelomir PharmaceuticalsN/A$4.42+5.2%N/AN/A$130.88MN/A0.001News CoverageSKYESkye Bioscience1.2915 of 5 stars$4.30+0.5%$18.67+334.1%+152.9%$130.46MN/A0.0011Insider Trade Related Companies and Tools Related Companies RAIN Alternatives SCYX Alternatives BOLT Alternatives SBBP Alternatives IPHA Alternatives SGMT Alternatives IXHL Alternatives BDTX Alternatives TELO Alternatives SKYE Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELEV) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevation Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELEV Stock Alerts